Skip to main content
OpenTrials
Completed

NCT Number: NCT00993226

An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy

The objective is to identify the optimal dose of SABER-Bupivacaine for postoperative pain control in patients undergoing hysterectomy on the basis of pharmacokinetics, efficacy and safety evaluations. The study duration consists of a screening period up to 14 days and a treatment period 14 days with a long term follow up visit at 6 months. The study will provide further data on the efficacy and safety of the product.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Nycomed, Paris, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A planned elective, abdominal hysterectomy
  • Patients suitable for general anaesthesia

Exclusion criteria

  • Known clinically significant hepatic, gastrointestinal, renal, haematological, urologic, neurological, respiratory, endocrine or cardiovascular system abnormalities
  • Known serious uncontrolled illness: cancer, psychiatric or metabolic disturbances. History of cured localised malignancies is allowed (i.e. basal or squamous cell skin carcinoma, breast carcinoma or cervical carcinoma)
  • Abnormal ECG
  • Prolonged QT syndrome
  • Current or regular use of analgesic medication for other indication(s)

Treatment and study plan

SABER-Bupivacaine Treatment 1a

Drug

5.0 ml

Placebo SABER-Bupivacaine Treatment 1b

Drug

5.0 ml

Other names: POSIMIR® bupivacaine solution

Bupivacaine HCl Treatment 1c

Drug

40 ml

SABER-Bupivacaine Treatment 2a

Drug

7.5 ml

Placebo SABER-Bupivacaine Treatment 2b

Drug

7.5 ml

Bupivacaine HCl Treatment 2c

Drug

40 ml

Primary outcomes

  1. Pain Intensity (PI)

    Time frame: 1 to 72 hours post-surgery

    Pain intensity (PI) on movement AUC over the period 1 to 72 hours post-surgery. Subjects assessed their pain intensity using an 11-point Pain Intensity Numeric Rating Scale (PI-NRS) with NRS scores ranging from 0 (no pain) to 10 (worst pain possible). The AUC is computed for each patient using the standard trapezoidal rule and normalised by dividing by the time interval over which it is computed. This normalisation converts the AUC to the natural pain scale (NRS 0-10) to allow for better translation of the clinical treatment effect magnitude.

  2. Supplemental Opioid Use

    Time frame: 0-3 days after surgery

    Cumulative IV morphine-equivalent dose of opioid rescue medication

Secondary outcomes

  1. Time to First Opioid Rescue Medication Usage

    Time frame: 0-14 days after surgery

  2. Opioid Related Side Effects

    Time frame: 0-7 days after surgery

    Opioid-related side effects were recorded 0-7 days after surgery. The Opioid-Related Symptom Distress Scale (OR-SDS) is a composite score computed from a questionnaire containing frequent opioid-related symptoms (Fatigue, Drowsiness, Inability to concentrate, Nausea, Dizziness, Constipation, Itching, Difficulty with urination, Confusion, Retching/vomiting). For each symptom, patients assigned integer scores to assess severity (none=0 to very severe=4), bothersomeness (none=0 to very much=5), and frequency (none=0 to almost constantly=4); patients reported number of Retching/vomiting episodes (none=0, 1-2 episodes=1, 3-4 episodes=2, 5-6 episodes=3, >6 episodes=4).

    On each day (Day 0-7), the score for each symptom was the mean of the three component scores, and the OR-SDS score was the overall mean of the 10 symptom scores, (values from 0 to 4; larger outcomes are worse). The mean of the daily OR-SDS score from Day 0 to 7 gave the overall OR-SDS Score.

Sponsors and collaborators

Lead sponsor

Durect

Industry

Collaborators

  • Nycomed

Registry information

Official study title

An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Undergoing Primary, Elective, Open, Abdominal Hysterectomy

Important dates

Study start
2009
Primary completion
2009
Study completion
2010
First posted
Oct 12, 2009
Registry last updated
Jun 1, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.